MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapies for the treatment of serious diseases with unmet medical needs in the United States. The company is headquartered in La Jolla, California.
| Revenue (TTM) | 596,640 |
| Gross Profit (TTM) | 47,930 |
| EBITDA | $-12.90M |
| Operating Margin | -1517.00% |
| Return on Equity | -26.20% |
| Return on Assets | -17.00% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.80 |
| Price-to-Book | 1.80 |
| Price-to-Sales (TTM) | 115.50 |
| EV/Revenue | 73.27 |
| EV/EBITDA | -2.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $49.22M |
| Float | $42.26M |
| % Insiders | 2.88% |
| % Institutions | 11.04% |
Volatility is currently expanding
LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D.
LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM).
